Investors’ perspective on investing in MedTech post COVID-19
Principal at Asabys, Sylvain joined the firm in 2018 from Ysios Capital. At Asabys, Sylvain is involved in the sourcing, execution, and management of our investments in the biopharma and medtech segments. He currently serves on the board of directors of Anaconda and SpliceBio and is an observer on the boards of Inbrain Neuroelectronics and Medlumics.
Previously, Sylvain spent a decade in academic labs both in France and the US, working specifically in the fields of gene therapy and regenerative medicine. He was a postdoctoral fellow in the department of Genetics and Genomic Sciences at the Mount Sinai School of Medicine in New York following the completion of his doctoral thesis at INSERM.
Sylvain obtained his Ph.D. in Molecular Medicine from University of Nantes, holds a master’s degree in biotechnology with honors from University Paris XII, and an MBA from Esade Business School in Barcelona.